Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Citi
Julphar
McKinsey
AstraZeneca
Moodys
Covington
Cerilliant
McKesson

Generated: December 15, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR PROBUCOL

« Back to Dashboard

Clinical Trials for Probucol

Trial ID Title Status Sponsor Phase Summary
NCT00276133 Effects of Atorvastatin Versus Probucol on Small Dense LDL Completed Yokohama City University Medical Center Phase 4 Small dense low-density lipoprotein (LDL) plays an important role in causing glomerular injury through conversion to an oxidatively modified form of LDL. However, few studies evaluated the effects of antilipidemic agents on the LDL particle size and renoprotective actions in hyperlipidemic patients with non-diabetic nephropathy.
NCT00426348 A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy Completed Guangdong General Hospital Phase 4 a statement of the study hypothesis:the effect of valsartan in patients with IgA nephropathy have been proved,and the efficacy of probucol in combination with valsartan is to be proved in patients with IgA nephropathy. This is a prospective randomized controlled, double blinded pilot study to identify the efficacy of probucol in combination with valsartan in patients with IgA nephropathy. The renal function deterioration will be the primary outcome studied. The expected study duration will be 36 months.
NCT00549978 Safety and Pharmacokinetics of Probucol and Cilostazol Completed Otsuka Pharmaceutical Co., Ltd. Phase 4 to investigate the safety and pharmacokinetics, in healthy adult male subjects
NCT00549978 Safety and Pharmacokinetics of Probucol and Cilostazol Completed Korea Otsuka Pharmaceutical Co., Ltd. Phase 4 to investigate the safety and pharmacokinetics, in healthy adult male subjects
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Probucol

Condition Name

Condition Name for Probucol
Intervention Trials
Healthy 3
Diabetic Nephropathy 2
Intracranial Hemorrhages 2
Type 2 Diabetes Mellitus 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Probucol
Intervention Trials
Kidney Diseases 5
Diabetes Mellitus 2
Hyperlipidemias 2
Intracranial Hemorrhages 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Probucol

Trials by Country

Trials by Country for Probucol
Location Trials
Korea, Republic of 22
China 10
Canada 1
Japan 1
Philippines 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Probucol

Clinical Trial Phase

Clinical Trial Phase for Probucol
Clinical Trial Phase Trials
Phase 4 12
Phase 3 1
Phase 2 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Probucol
Clinical Trial Phase Trials
Completed 12
Active, not recruiting 4
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Probucol

Sponsor Name

Sponsor Name for Probucol
Sponsor Trials
Korea Otsuka Pharmaceutical Co., Ltd. 8
Otsuka Beijing Research Institute 7
Guangdong General Hospital 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Probucol
Sponsor Trials
Industry 16
Other 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Teva
Fuji
Queensland Health
US Department of Justice
Moodys
Colorcon
Covington
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.